In many published papers, different methods to detect MRD in AML patients (e.g., multiparameter flow cytometry, WT1 levels, molecular chimerism,...) have been compared, but none emerged as more powerful than another in predicting disease relapse [8, 12, 17, 19]. This evidence concerns the gene WT1 and acute myeloid leukemia.